Skip to main content
Mezzion Pharma Co., Ltd. logo

Mezzion Pharma Co., Ltd. — Investor Relations & Filings

Ticker · 140410 ISIN · KR7140410002 KO Manufacturing
Open in API
Filings indexed 218 across all filing types
Latest filing 2024-07-03 Director's Dealing
Country KR South Korea
Listing KO 140410

About Mezzion Pharma Co., Ltd.

https://mezzion.com

Mezzion Pharma Co., Ltd. is an innovation-driven pharmaceutical company focused on discovering, developing, and commercializing novel therapeutics for rare diseases. The company's primary efforts are concentrated on addressing the unmet medical needs of individuals with a Fontan circulation, a palliative surgical procedure for single-ventricle heart defects. Its lead drug candidate, udenafil, is being advanced as a potential first-to-market treatment to improve the physiology of the Fontan circulation. Mezzion is conducting late-stage clinical development, including a confirmatory Phase 3 trial (FUEL-2), to evaluate the therapy's efficacy in adolescent patients.

Recent filings

Filing Released Lang Actions
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 1% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean Financial Supervisory Service. This type of filing is a standard regulatory requirement for insiders (executives/directors) to disclose their personal share transactions. Based on the provided definitions, this falls under 'Director's Dealing' (DIRS), which covers personal share transactions by company directors and executives.
2024-07-03 Korean
[기재정정]주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 1% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding of Stocks, etc.), which is a standard regulatory filing in South Korea (often referred to as a 5% report). It details changes in share ownership, special relationships, and major contracts. This falls under the category of Major Shareholding Notification.
2024-06-19 Korean
분기보고서 (2024.03)
Interim / Quarterly Report Classification · 1% confidence The document is a '분기보고서' (Quarterly Report) for the first quarter of 2024, submitted by Mezzion Corporation to the Financial Services Commission and the Korea Exchange. It contains detailed financial information, business operations, and management discussions for the specified period, fitting the definition of an Interim/Quarterly Report. Q1 2024
2024-05-14 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 1% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean Financial Supervisory Service (DART). This type of filing is a mandatory disclosure of insider trading or changes in share ownership by company directors or major shareholders. According to the provided definitions, this corresponds to 'Director's Dealing' (DIRS).
2024-04-23 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 1% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details the shareholding status, changes in ownership, and the purpose of holding (management influence) for major shareholders and special related parties of the company 'Mezzion'. This type of filing is specifically categorized as a 'Major Shareholding Notification' (MRQ) in the provided schema.
2024-04-23 Korean
[첨부추가]투자판단관련주요경영사항(임상시험계획변경승인) (폰탄환자치료제 유데나필의 임상3상(추가 임상) 임상시험 계획 변경승인)
Regulatory Filings Classification · 1% confidence The document is a regulatory filing from a Korean company (Mezzion) regarding the approval of a clinical trial plan amendment by the Ministry of Food and Drug Safety (MFDS). It follows the standard format for 'Major Management Matters' (주요경영사항) filings on the KRX (Korea Exchange). Since it details a specific regulatory event regarding clinical trials and does not fit into the other specific categories like financial reports or shareholder meetings, it is classified as a Regulatory Filing (RNS).
2024-04-08 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.